about
Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapyAnti-inflammatory dimethylfumarate: a potential new therapy for asthma?Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis.Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview.Identification of protein succination as a novel modification of tubulinFumaric acid esters can block pro-inflammatory actions of human CRP and ameliorate metabolic disturbances in transgenic spontaneously hypertensive rats.Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A/J model of lung carcinogenesisDrug-induced Fanconi syndrome associated with fumaric acid esters treatment for psoriasis: a case series.Multiple sclerosis: Five new things.Dimethyl fumarate restores apoptosis sensitivity and inhibits tumor growth and metastasis in CTCL by targeting NF-κB.Microparticulate/Nanoparticulate Powders of a Novel Nrf2 Activator and an Aerosol Performance Enhancer for Pulmonary Delivery Targeting the Lung Nrf2/Keap-1 Pathway.The use of immune modulating drugs for the treatment of multiple sclerosis.Established and novel disease-modifying treatments in multiple sclerosis.Dimethylfumarate protects against TNF-α-induced secretion of inflammatory cytokines in human endothelial cells.Protein phosphatase 2Cδ/Wip1 regulates phospho-p90RSK2 activity in lesional psoriatic skin.The nuclear factor (erythroid-derived 2)-like 2 (NRF2) antioxidant response promotes melanocyte viability and reduces toxicity of the vitiligo-inducing phenol monobenzone.Fumaric acid esters in the management of psoriasis.
P2860
Q26738969-12A60BF8-EB37-4531-A60E-EF273C3204C7Q26853672-B209E2D7-343B-4D9A-8E47-E5D97A0C9A39Q33755345-5127AFFE-1CB5-4C06-B9F3-A807C47B9C76Q34667496-CB9B0DA0-5026-46FA-97E0-4C6B88E07ED8Q35073301-E9540351-7874-486D-A735-1B38BD9DD986Q35204440-03D6FBC0-D37D-4866-B7CF-F852FCF8A9B8Q36067904-0784287F-D92C-48D6-A9A9-470B07745B82Q36482880-CF0A84F5-7D5D-4A4D-BDD4-178678AEE6EFQ37251695-4CA29E7E-C3F1-47BF-8BDF-6D5442D4DDE1Q37262461-A127AA79-4A11-4398-AF2A-B99785312B50Q37354043-59850CC5-0395-4E21-B83A-51A9FC32DFE5Q37577290-A4F98C86-C986-4E20-A797-D83E811E6AC9Q38180157-A2583C76-D8B3-491F-B80A-50F996023181Q42418083-CF1D908B-A1BD-4AB9-B9FC-5C363DAAB176Q47106368-803BA9D8-3667-4F3E-9C85-01F787532F64Q48333222-F91CDBDD-75E7-4077-8C21-0E5690E4E559Q54958047-BFC79A4E-26A8-402A-BBFB-B50642BDEEBD
P2860
description
im August 2012 veröffentlichter wissenschaftlicher Artikel
@de
наукова стаття, опублікована в серпні 2012
@uk
name
Dimethyl fumarate - only an anti-psoriatic medication?
@en
type
label
Dimethyl fumarate - only an anti-psoriatic medication?
@en
prefLabel
Dimethyl fumarate - only an anti-psoriatic medication?
@en
P2093
P2860
P1433
P1476
Dimethyl fumarate - only an anti-psoriatic medication?
@en
P2093
Eva Maria Valesky
Markus Meissner
Roland Kaufmann
Stefan Kippenberger
P2860
P304
P356
10.1111/J.1610-0387.2012.07996.X
P577
2012-08-17T00:00:00Z